<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105429</url>
  </required_header>
  <id_info>
    <org_study_id>MB122-002</org_study_id>
    <nct_id>NCT01105429</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes</brief_title>
  <official_title>Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-820132 in Subjects With Type 2 Diabetes on Background Therapy of Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BMS-820132 is an investigational new drug being developed by BMS for treating Type 2
      diabetes. The purpose of this study is to test the safety/tolerability (potential side
      effects) of single doses of the investigational new drug, as well as the amount of study drug
      in the blood, in subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of the investigational drug, as assessed by adverse event monitoring, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments</measure>
    <time_frame>Within 5 days of study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exposure to the investigational drug and its metabolites</measure>
    <time_frame>Within 2 days after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity of the investigational drug on biomarkers</measure>
    <time_frame>Within 2 days after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excretion of the investigational drug and metabolites from the body</measure>
    <time_frame>Within 2 days after study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <arm_group>
    <arm_group_label>BMS-820132 (0.3 mg) or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820132 (1.0 mg) or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820132 (3 mg) or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820132 (10 mg) or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820132 (30 mg) or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820132 (75 mg) or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820132 (150 mg) or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820132 (300 mg) or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820132 (TBD) or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Oral Solution, Oral, 0.3 mg, once daily, 1 day</description>
    <arm_group_label>BMS-820132 (0.3 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Oral Solution, Oral, 1.0 mg, once daily, 1 day</description>
    <arm_group_label>BMS-820132 (1.0 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Oral Solution, Oral, 3 mg, once daily, 1 day</description>
    <arm_group_label>BMS-820132 (3 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Oral Solution, Oral, 10 mg, once daily, 1 day</description>
    <arm_group_label>BMS-820132 (10 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Oral Solution, Oral, 30 mg, once daily, 1 day</description>
    <arm_group_label>BMS-820132 (30 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Oral Solution, Oral , 75 mg, once daily, 1 day</description>
    <arm_group_label>BMS-820132 (75 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Oral Solution, Oral, 150 mg, once daily, 1 day</description>
    <arm_group_label>BMS-820132 (150 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Oral Solution, Oral, 300 mg, once daily, 1 day</description>
    <arm_group_label>BMS-820132 (300 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Capsule, Oral, (TBD), once daily, 2 days</description>
    <arm_group_label>BMS-820132 (TBD) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Solution, Oral, 0mg, once daily, 1 day</description>
    <arm_group_label>BMS-820132 (0.3 mg) or Placebo</arm_group_label>
    <arm_group_label>BMS-820132 (1.0 mg) or Placebo</arm_group_label>
    <arm_group_label>BMS-820132 (3 mg) or Placebo</arm_group_label>
    <arm_group_label>BMS-820132 (10 mg) or Placebo</arm_group_label>
    <arm_group_label>BMS-820132 (30 mg) or Placebo</arm_group_label>
    <arm_group_label>BMS-820132 (75 mg) or Placebo</arm_group_label>
    <arm_group_label>BMS-820132 (150 mg) or Placebo</arm_group_label>
    <arm_group_label>BMS-820132 (300 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule, Oral, (TBD), once daily, 2 days</description>
    <arm_group_label>BMS-820132 (TBD) or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females of childbearing potential (willing to use an acceptable method of
             contraception), or females of non-childbearing potential (i.e., post-menopausal or
             surgically sterile)

          -  Diagnosis of type 2 diabetes treated with metformin monotherapy on a stable regimen
             for at least 2 months

          -  Body Mass Index (BMI) of 18 to 40 kg/m2

          -  Fasting glucose in the range of 100-250 mg/dL

          -  Hemoglobin A1c (HbA1c) in the range of 6.5% -9.5%

        Exclusion Criteria:

          -  Clinically significant deviation from normal in medical history, physical examination,
             ECGs, and clinical laboratory determinations

          -  Any significant acute or chronic medical illness other than stable and well controlled
             hypertension, microalbuminuria, dyslipidemia, or depression

          -  Past history of diabetic ketoacidosis and/or C-peptide &lt; 1.0 ng/mL, hyperosmolar
             nonketotic syndrome, lactic acidosis, or recurrent hypoglycemia

          -  Any major surgery within 4 weeks of study drug administration

          -  Any gastrointestinal surgery that could impact upon the absorption of study drug

          -  Smoking more than 10 cigarettes per day

          -  Recent drug or alcohol abuse

          -  Women who are pregnant or breastfeeding

          -  Positive urine screen for drugs of abuse

          -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1,
             -2 antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute For Clinical Research, Inc. (Picr)</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Of Miami Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2010</study_first_posted>
  <last_update_submitted>March 8, 2011</last_update_submitted>
  <last_update_submitted_qc>March 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

